Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group (Q34069128)

30 July 2017

1 reference

title

Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group (English)

1 reference

30 July 2017

Volberding P

1

1 reference

30 July 2017

language of work or name

1 reference

1 September 2000

1 reference

30 July 2017

published in

Clinical Therapeutics

1 reference

30 July 2017

volume

22

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

1004-1020; discussion 1003

1 reference

Anemia and survival in HIV infection

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

The Use of Hematopoietic Growth Factors in HIV Infection and AIDS-Related Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Serum immunoreactive erythropoietin in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Management of the hematologic complications of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Mycobacterium avium complex infection in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Hydroxyurea in the treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Transfusion practices in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Iron overload in multiply transfused patients who are HIV seropositive

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Recombinant human erythropoietin in the treatment of the anaemia of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Red cell autoantibodies in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Practice strategies for elective red blood cell transfusion. American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980081-8

7 January 2021

10.1016/S0149-2918(00)80081-8

Identifiers

DOI

1 reference

30 July 2017

1 reference